This suit was surfaced by Law.com Radar. Read the complaint here.
Curative is shifting from COVID-19 testing to launching a new health plan as testing needs decrease.
To thrive in this speedily transforming marketplace, today’s businesses call for innovative and superlative solutions. Digital Therapeutic (Dtx) is the
It’s time again to check the pulse — of Florida’s health care policy and politics.
Region wise, Europe is expected to experience growth at the highest rate, registering a CAGR of 21.5% during the forecast period.
Pear Therapeutics, Inc. (NASDAQ:PEAR - Get Rating) major shareholder 5Am Partners Iv, Llc sold 285,067 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The shares were sold at an average price of $1.94, for a total value of $553,029.98. Following the comple…
Pear Therapeutics, Inc. (NASDAQ:PEAR - Get Rating) was the recipient of a significant increase in short interest during the month of August. As of August 31st, there was short interest totalling 769,200 shares, an increase of 37.4% from the August 15th total of 559,900 shares. Currently, 1.3% of th…
The North American region emerged as the largest market for the global Digital Therapeutics market, with a 35.3% share of the market revenue in 2021.
Multiple sclerosis pipeline constitutes 100 key companies continuously working towards developing 100 Multiple sclerosis treatment therapies analyzes DelveInsight Multiple sclerosis MS is a chronic autoimmune disease of the central nervous system CNS characterized by inflammation demyelination glios…
Pear Therapeutics, Inc. (NASDAQ:PEAR), the leader in developing and commercializing software-based medicines called prescription digital therapeutics (PDTs), today announced the company will participate in the LifeSci
On September 1, 2022, the South Carolina Department of Corrections (SCDC) announced plans with Pear Therapeutics, Inc. for a pilot to offer Pear’s prescription digital therapeutics (PDT) to women inmates … Continued
BOSTON, September 07, 2022--Pear Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
Shares of Pear Therapeutics, Inc. (NASDAQ:PEAR - Get Rating) have received an average rating of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company
To get a sense of who is truly in control of Pear Therapeutics, Inc. ( NASDAQ:PEAR ), it is important to understand the...
South Carolina Department of Corrections and Pear Therapeutics Team up to Support Inmates in Recovery from Substance Use Disorders
The internal medicine physician and chief medical officer and head of development at Pear Therapeutics spoke about the long-term impacts that uncontrolled insomnia can have on patients with chronic disease. [WATCH TIME: 3 minutes]
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alnylam, Bio-Techne, Cerveau, Fluidx, Openeye, Pharmajet, Sense Biodetection, Tecomedical.
Gainers Micro Focus International plc (NYSE: MFGP) shares surged 92% to close at $6.01 on Friday after the company reached an agreement with OpenText to be acquired for $6 billion.
Here is a detailed account of Austin Hearst’s net worth and career. He is one of the richest producers in the world.
The internal medicine physician, and chief medical officer and head of development at Pear Therapeutics discussed the findings of a recent study assessing cognitive behavioral therapy for insomnia. [WATCH TIME: 4 minutes]